IL107003A0 - 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man - Google Patents

3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Info

Publication number
IL107003A0
IL107003A0 IL107003A IL10700393A IL107003A0 IL 107003 A0 IL107003 A0 IL 107003A0 IL 107003 A IL107003 A IL 107003A IL 10700393 A IL10700393 A IL 10700393A IL 107003 A0 IL107003 A0 IL 107003A0
Authority
IL
Israel
Prior art keywords
pyrrolo
disubstituted
dihydro
heterocyclic
man
Prior art date
Application number
IL107003A
Other languages
English (en)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of IL107003A0 publication Critical patent/IL107003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL107003A 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man IL107003A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/947,152 US5278162A (en) 1992-09-18 1992-09-18 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Publications (1)

Publication Number Publication Date
IL107003A0 true IL107003A0 (en) 1993-12-28

Family

ID=25485622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL107003A IL107003A0 (en) 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Country Status (10)

Country Link
US (1) US5278162A (enExample)
EP (1) EP0660833A1 (enExample)
JP (1) JPH08501550A (enExample)
CN (1) CN1094406A (enExample)
AU (1) AU4856893A (enExample)
CA (1) CA2144636A1 (enExample)
IL (1) IL107003A0 (enExample)
TW (1) TW248560B (enExample)
WO (1) WO1994006793A1 (enExample)
ZA (1) ZA936872B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
AU1884595A (en) 1994-04-29 1995-11-29 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
MX2009003875A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
AU2007319580B2 (en) * 2006-10-12 2012-11-29 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
BRPI0920448A2 (pt) * 2008-10-17 2018-10-23 Xenon Pharmaceuticals Inc. compostos spiro-oxindol e seu uso como agentes terapêuticos
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047174A1 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
EP0419561A1 (en) * 1988-06-14 1991-04-03 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
TW248560B (enExample) 1995-06-01
CN1094406A (zh) 1994-11-02
EP0660833A1 (en) 1995-07-05
US5278162A (en) 1994-01-11
JPH08501550A (ja) 1996-02-20
WO1994006793A1 (en) 1994-03-31
ZA936872B (en) 1995-03-17
AU4856893A (en) 1994-04-12
CA2144636A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
IL107003A0 (en) 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man
ZA904991B (en) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'-e)(1,4)-diazepin-6-ones and-thiones and their use for the treatment of aids
GB9226860D0 (en) Novel treatment
KR970000398B1 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane
GB9203039D0 (en) Treatment
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
GB9201920D0 (en) Novel treatment i
ZA931063B (en) Treatment of glaucoma.
EP0557949A3 (en) Process for the preparation of 2,4,5 trifluorobenzonitrile
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
PH27414A (en) 1,2,4-oxadiazolyl-phenoxy-alkylisoxazoles and their use as antiviral agents
ZA933376B (en) Novel treatment
GB9214373D0 (en) Newadjustable "photo-back"
GB2282529B (en) Baby's bath
GB9225859D0 (en) Novel treatment
ZA936874B (en) Process for the preparation of 5,6-diacetoxyindole
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
GB9607420D0 (en) Formulations of mannose phosphates useful in the treatment of fibrotic disorders
IL100629A0 (en) Apparatus for the treatment of papulosquamous disorders
GB9204036D0 (en) The"secura-grip"
GB9220588D0 (en) The "trailersafe"
CA70342S (en) Surgeon's hood